The value of the market for cancer vaccines has the potential to reach $6 billion by 2010, according to Arrowhead Publishers, who have just released their new report Cancer Vaccines: Measuring Market Potential. (http://www.arrowheadpublishers.com/CancerVaccines.html)
(PRWEB) January 5, 2005 -- Vaccines represent fresh new treatment options for patients diagnosed with melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, pancreatic cancer, and other life-threatening cancers. There are currently over twenty Phase III trials ongoing for various indications and new approvals may come as early as 2005.
This report includes the latest clinical data and analysis concerning the leading vaccines and the companies making them, allowing the reader to benchmark the competition and determine need in this growing field.
In addition, financial forecasts are provided for vaccines set to make an impact on distinct cancer markets. Moreover, their upcoming market entrance is discussed within the context of current and future biologic and small-molecule competition.
Therapeutic cancer vaccines have the potential to strengthen the body's natural defenses against cancers that have already developed. These vaccines may thus, prevent the further growth of existing cancers, prevent recurrence of treated cancers, or kill cancer cells not killed by other treatments.
This new 232-page report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a wide range of cancer markets. It is designed to provide the information, insight, and analysis necessary to an understanding of how cancer vaccines will impact the biotech and pharmaceutical marketplace. Those in the field of cancer therapy will want to read this report in order to better understand where and how vaccines will make a difference in future cancer therapy.
Cancer Vaccines: Measuring Market Potential
• Gauges the potential of key vaccine products nearing commercialization.
• Analyzes the results of key clinical trials as a means of determining future success in the market.
• Forecasts financial growth of the cancer vaccine market through 2010.
• Assesses the competition from cytotoxics and other biologics in six key cancer markets.
• Provides valuable data concerning patient populations, survival rates, and global epidemiology
• Identifies and discusses trends and issues that will have a significant impact on the cancer vaccine market.
• Profiles the leading companies in the field and provides valuable information and analysis concerning their lead vaccine candidates.
Contact:
Sales Department
952-474-5203
www.arrowheadpublishers.com
# # #
|
